Oncology Brothers: Practice-Changing Cancer Discussions

Open Evidence as an Artificial Intelligence (AI) Tool in the World of Medicine

In this episode of the Oncology Brothers podcast, we dived into the transformative role of artificial intelligence (AI) in oncology and medical practice. Joined by Dr. Travis Zack, Chief Medical Officer of Open Evidence, we explored how large language models (LLMs) are revolutionizing the way clinicians access and utilize medical information.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11oApple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Key topics included:
The rapid evolution of AI in healthcare and its implications for patient care.
How Open Evidence differentiates itself by focusing on reliable medical sources like NCCN, NEJM, and JAMA.
The importance of integrating AI tools into clinical workflows to enhance decision-making and patient outcomes.
The business model behind Open Evidence and the ethical considerations regarding data usage.
Future prospects for AI in oncology, including potential integration with electronic health records (EHRs) and clinical trials.
Join us as we discuss the exciting advancements in AI technology and how they can empower oncologists to provide better care for their patients. Don't miss this insightful conversation that highlights the intersection of technology and medicine!
Subscribe to our channel for more episodes on FDA approvals, conference highlights, and treatment algorithms in oncology!
#AIinHealthcare #Oncology #MedicalAI #CancerResearch #HealthcareInnovation #OncBrothers

How to Treat Renal Cell Carcinoma (RCC) in 2026 – Dr. Katy Beckermann

Welcome back to the Oncology Brothers podcast! In this episode, we discussed current treatment landscape and updates from GU ASCO 2026, with focus on kidney cancer.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
We were joined by Dr. Katy Beckermann, a medical oncologist from Tennessee Oncology, to discuss:
The current standard of care for renal cell carcinoma (RCC), including adjuvant treatment options post-surgery.
The implications of the KEYNOTE-564 study and the approval of Pembrolizumab for high-risk RCC patients.
Insights from the LITESPARK- 022 trial, comparing Pembrolizumab with the combination of Pembrolizumab and Belzutifan in the adjuvant setting.
The challenges of undertreatment versus overtreatment in kidney cancer therapy, including side effects and financial toxicity.
Strategies for managing metastatic disease, including re-challenging immunotherapy and the role of IMDC criteria in treatment decisions.
The promising data from LITESPARK-011, exploring the combination of Lenvatinib and Belzutifan in the second-line setting.
Tune in for an informative discussion that covers the latest research, clinical practices, and expert opinions in the field of kidney cancer. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology!
#KidneyCancer, #RenalCellCarcinoma, #GUASCO2026, #OncBrothers

Evolving Treatment Landscape of HER2+ Upper GI Cancer

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the current treatment landscape for frontline HER2-positive gastroesophageal junction (GEJ) and gastric cancer.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11oApple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Join us as we welcome Dr. Sunnie Kim from the University of Colorado and Dr. Samuel Cytryn from Memorial Sloan Kettering, who shared their insights on the latest advancements in HER2-targeted therapies. We discussed the pivotal TOGA and KEYNOTE-811, the promising data from the HERIZON-GEA01 study featuring Zanidatamab, and the implications of these findings for clinical practice.
Key topics included:
Current standard of care for HER2-positive GEJ and gastric cancer
The role of PD-L1 status in treatment decisions
Mechanisms and efficacy of Zanidatamab compared to traditional therapies
Management of side effects, including diarrhea and infusion-related reactions
Future directions in HER2-targeted therapies, including T-DXd based on the DESTINY Gastric-04 trial
Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms, FDA approvals, and conference highlights!
Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:https://www.gotoper.com/courses/new-precision-strategies-for-her2-gea-interpreting-new-data-to-inform-clinical-practice

How to Treat Prostate Cancer Localized to Advanced Settings - Dr. Scott Tagawa

Welcome to the Oncology Brothers podcast! In this episode, we discussed the current treatment landscape for prostate cancer, featuring special guest Dr. Scott Tagawa, a GU Medical Oncologist from Weill Cornell Medicine.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Join us as we explored:
The current standard of care for localized prostate cancer, including active surveillance, surgery, and radiation.
The significance of ADT and abiraterone in high-risk disease, supported by the STAMPEDE trial.
The role of PSMA PET/CT in staging and how it impacts treatment decisions.
Treatment options for castration-sensitive and castration-resistant prostate cancer, including the use of ARPi and chemotherapy.
The importance of germline and somatic testing, especially with the recent approval of Niraparib for BRCA2-positive disease.
Insights on managing side effects and the nuances of patient-centered care in oncology.
Whether you're a healthcare professional or someone interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help you stay informed.
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#ProstateCancer, #ADT, #PSMA, #PARPinhibitor, #OncologyBrothers

Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

In this episode of the Oncology Brothers podcast, we were joined by two international experts — Professor Gary Tse, a pathologist from the Chinese University of Hong Kong, and Dr. Carlos Barrios, a medical oncologist from Brazil — to unpack the evolving landscape of HER2 testing in breast cancer. What was once a binary positive or negative classification has now expanded to include HER2-low and HER2-ultra-low, opening the door to new treatment options for the majority of breast cancer patients.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Key topics discussed included:
How HER2 classification has evolved from a binary result to a continuous spectrum including HER2-low and HER2-ultra-low, driven by the efficacy of antibody drug conjugates like T-DXd
Pre-analytical challenges in metastatic settings including tumor heterogeneity
The role of IHC, ISH, NGS, and liquid biopsy in HER2 assessment, and how each tool fits into clinical practice.
The importance of multidisciplinary collaboration between pathologists and oncologists to ensure accurate interpretation and optimal treatment selection.
Join us for this expert discussion on one of the most clinically impactful topics in breast oncology today. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!
#HER2, #BreastCancer, #BiomarkerTesting, #PrecisionOncology, #OncologyBrothers

GU ASCO 2026 Highlights – CREST, POTOMAC, EV-304/KEYNOTE-B15, LITESPARK-011/022, CAPITELLO-281

In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas, medical oncologist from the Fred Hutch Cancer Center, who walked through practice-changing and practice-reinforcing data across bladder cancer, kidney cancer, and prostate cancer.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Key topics discussed included:
CREST & POTOMAC: IO-BCG combination data in high-risk BCG-naive NMIBC, both demonstrating a hazard ratio of 0.68 for DFS / EFS.
EV-304/KEYNOTE-B15: established EV-Pembrolizumab as the new perioperative standard of care for resectable muscle-invasive bladder cancer regardless of cisplatin eligibility, with a pathological complete response rate of 56% and overall survival hazard ratio of 0.65.
LITESPARK-022 & LITESPARK-011: data exploring Belzutifan combinations in adjuvant and refractory RCC settings, while managing key toxicities of anemia and hypoxia.
CAPITELLO-281: evaluating capivasertib in PTEN-deficient metastatic hormone-sensitive prostate cancer, where patient related outcomes were reported. 
Join us for this comprehensive discussion covering the latest GU oncology advances that will directly impact your clinical practice. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!
#GUASCO2026, #BladderCancer, #RenalCellCarcinoma, #ProstateCancer, #OncBrothers

Clinical Insights: Evolving Landscape of Bladder Cancer After GU ASCO 2026

We had the opportunity to dive into the evolving landscape of bladder cancer treatment in this insightful podcast episode at GU ASCO 2026. Featuring expert guests Dr. Chad Reichard, Dr. Shilpa Gupta, Dr. Matt Galsky, and Dr. Sia Daneshmand, the discussion covered the latest FDA-approved options for muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC), and exciting data that we are seeing presented at GU ASCO 2026.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11oApple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
In this episode, you'll learn about:
The current treatment options for MIBC, including neoadjuvant Gem/Cis with perioperative durvalumab vs. EV/pembrolizumab combination
Key findings from pivotal studies like KEYNOTE-905, NIAGARA, and KEYNOTE-B15
The implications of these studies on clinical practice and patient management
The importance of a multidisciplinary approach in treating bladder cancer
Emerging data on BCG plus immunotherapy combinations for NMIBC and their potential impact on treatment protocols
Tune in for a comprehensive discussion that highlights the importance of collaboration between medical oncologists and urologists in optimizing patient care.Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!#BladderCancer, #MIBC, #NMIBC, #Immunotherapy, #EVpembro

Teclistamab-Daratumumab FDA Approval of MajesTEC-3 for R/R Multiple Myeloma (MM): Dr. Luciano Costa

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of multiple myeloma treatment, focusing on the groundbreaking MajesTEC-3 trial. We had the pleasure of welcoming Dr. Luciano Costa from the University of Alabama, who shared insights on the combination of teclistamab and daratumumab for relapsed refractory multiple myeloma.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Key topics discussed included:
The impressive progression-free survival (PFS) rates observed in the MajesTEC-3 trial, with a PFS of 83.4% at three years.
The mechanism of action of teclistamab as a bispecific antibody targeting BCMA and its synergy with daratumumab.
Safety profiles, including the management of cytokine release syndrome (CRS) and infection risks, along with the use of IVIG for prophylaxis.
The evolving landscape of multiple myeloma therapies, including the role of CAR T-cell therapy versus bispecific antibodies.
Join us for this informative discussion that aims to keep healthcare professionals updated on the latest advancements in multiple myeloma treatment. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology!
#MultipleMyeloma, #MajesTEC3, #Teclistamab, #Daratumumab, #BispecificAntibody, #OncBrothers

Triple Negative Breast Cancer (TNBC) Treatment Algorithm: Dr. Tiffany Traina

Welcome to the Oncology Brothers podcast! In this episode we continue our series on breast cancer treatment algorithms, focusing specifically on triple negative breast cancer (TNBC). We welcomed Dr. Tiffany Traina, a breast medical oncologist from the Memorial Sloan Kettering Cancer Center, to discuss the latest advancements in the management of TNBC. We dived deep into the treatment algorithm for early-stage disease, including the criteria for adjuvant chemotherapy, the use of neoadjuvant therapies like KEYNOTE-522, and the importance of balancing risk and benefit in treatment decisions.
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Key topics covered in this episode included:* Criteria for adjuvant chemotherapy in early-stage TNBC* The role of pembrolizumab in neoadjuvant and adjuvant settings* Management of residual disease with capecitabine and olaparib* Insights into the latest clinical trials, including ASCENT-03, ASCENT-04, and TROPION-Breast02* Side effect management strategies for new therapies
Don't forget to subscribe for more episodes in our breast cancer series, and feel free to send us your questions and cases!
Listen now and stay informed on the evolving landscape of triple negative breast cancer treatment!
#TripleNegativeBreastCancer, #TNBC, #Pembrolizumab, #ADC, #OncologyBrothers

Combination Approaches in PD-L1–Positive Metastatic Triple Negative Breast Cancer

Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving frontline treatment landscape for triple-negative breast cancer (TNBC).
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers•⁠  Website: https://oncbrothers.com/
Join us as we welcomed Dr. Sherene Loi, a leading breast medical oncologist from Australia, to discuss the challenges of treating TNBC and the exciting new treatment options available. We explored the significance of PD-L1 scoring in metastatic TNBC, the implications of recent trials like ASCENT-04, and the potential of antibody-drug conjugates (ADCs) such as sacituzumab govitecan and datopotamab deruxtecan.
Key topics included:• The role of PD-L1 positivity in treatment decisions• Insights from the ASCENT-04 trial and its findings• Common side effects associated with sacituzumab and strategies for management• The future of immunotherapy and ADCs in TNBC treatment
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable information and clinical pearls. Don't forget to subscribe for more insightful discussions on cancer treatment!
#TNBC, #PDL1positive, #ASCENT04, #Immunotherapy, #OncBrothers